Data from the FOREST-HCM trial's 46-person cohort with one-year follow-up provide clinicians with further insight into the long-term effects of afficamten in patients with hypertrophic cardiomyopathy.
Latest data from the FOREST-HCM study, presented at the American College of Cardiology 2024 (ACC.24) Annual Scientific Sessions, showed significant and sustained reductions in left ventricular outflow tract gradient (LVOT-G), symptoms and cardiac biomarkers. details the improvements. We use aficamten, a cardiac myosin inhibitor from Cytokinetics.1
“What we're actually seeing is a rapid, fairly strong, and sustained reduction in outflow obstruction with preservation of left ventricular systolic function over that period of time, and we're seeing a rapid, fairly strong, and sustained reduction in outflow obstruction with preservation of left ventricular systolic function over that period of time, and we're seeing a We're also seeing significant improvements in how patients are reported,” lead researcher Sara Saberi, M.D., associate professor of internal medicine at the Frankel Heart and Vascular Center at the University of Michigan Health, said in an interview with HCPLive.
The ongoing study, FOREST-HCM, is an open-label extension study in patients from the REDWOOD-HCM or SEQUOIA-HCM trials. As of April 5, 2024, the trial included more than 200 participants, with 46 patients having at least 48 weeks of follow-up as of the interim analysis presented at ACC.24. Achieved.2, 3
Follow-up data from this cohort suggested that afficamten use was associated with a significant and sustained reduction in mean resting LVOT-G (mean change from baseline, -39.6 mmHg) [Standard deviation, 34]; P <.0001) and Valsalva LVOT-G (mean change from baseline, -53.2 mmHg) [SD, 38.6]; P <.0001). Further analysis showed that use was associated with statistically significant improvements in New York Heart Association (NYHA) functional classes from baseline, with 82.2% of patients improving by one or more NYHA classes, and in this cohort It was shown that no cases of deterioration were observed. Additionally, there was significant improvement in his NT-proBNP, a biomarker of heart wall stress, with an average decrease of 63% from baseline to his 48th week (P <.001).1
Researchers found that 19 of the 46 patients included in this analysis were considered eligible for septal reduction therapy at baseline, but only 1 patient remained eligible after 6 months. He emphasized that only. Additionally, no serious treatment-related adverse events were reported in this study, and left ventricular ejection fraction decreased slightly from baseline to week 48 (mean change from baseline -5.1 mg ). [SD, 5.9]; P <.0001).1
To learn more about the results and what they mean for clinicians as they await further data from the aficamten program, check out our interview with Saberi from the conference floor at ACC.24.
Disclosures related to Saberi include Cytokinetics and Bristol-Myers Squibb Company.
References:
- Saberi S, Abraham TP, Choudhury L et al., Hutchinson HG, Wolski K et al. Efficacy and safety of afficamten in the first cohort of patients with symptomatic obstructive hypertrophic cardiomyopathy who completed 1 year of follow-up: Results from the Forest-HCM study. Presentation location: American College of Cardiology (ACC.24) Annual Scientific Sessions. April 6-8, 2024, Atlanta, Georgia.
- Cytokinetics, Inc. Cytokinetics will present additional 48 weeks of data from Forest-HCM, an open-label extension clinical study of AFICAMTEN, at the American College of Cardiology's 73rd Annual Academic Session. Cytokinetics, Inc. April 5, 2024. Accessed April 11, 2024. https://ir.cytokinetics.com/news-releases/news-release-details/cytokinetics-presents-Additional-48-week-data-forest-hcm – Open.
- Hypertrophic cardiomyopathy clinical trial: Aficamten. Cell dynamics. April 10, 2024. Accessed April 11, 2024. https://cytokinetics.com/medicines-research/hypertrophic-cardiomyopathy-clinical-trials/.